Case-Based Roundtable®

This roundtable series assesses using Bruton kinase inhibitors in patients with chronic lymphocytic leukemia as first-line therapy, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series evaluates therapies for patients with relapsed/refractory multiple myeloma after they have recieved multiple types of treatment, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series explores options for anemic patients with myelofibrosis after they have received a JAK inhibitor, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews options after progression on platinum-regimens for patients with mismatch repair–deficient recurrent or advanced endometrial cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series discusses antibody-drug conjugates as therapy for patients with cervical cancer who had progressed on chemotherapy, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series examines options for patients with KRAS G12C-mutated non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers treatment options in the metastatic bladder cancer setting, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series assesses treatment after first-line progression for patients with deleterious germline or somatic homologous recombination repair-mutated metastatic castration-resistant prostate cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series evaluates the use of combination therapies using immunotherapy and chemotherapy in patients with advanced Hodgkin lymphoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews treatments in adult patients with multiple myeloma who have progressed on 1 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series explores therapies after progression on endocrine therapy in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer who have an ESR1 mutation,as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers the use of combination treatments in patients with relapsed/refractory multiple myeloma who have received 2 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series discusses immunotherapy treatment used in metastatic or unresectablemelanoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series examines systemic therapies and other options approvedin those with steroid-refractorychronic graft-vs-host disease, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series evaluates the use of frontline immunotherapy plus chemotherapy in locally advanced or metastatic biliary tract cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series provides context on the growing number of options for patients with non–small cell lung cancer and KRAS G12C mutations, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series assesses later-line treatment of patientswith relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers multiple therapies from published clinical trials for patients with relapsed/refractory metastatic clear cell renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews molecular testing in non–small cell lung cancer and potential treatments for patients with EGFR exon 20 mutations, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.

This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.

This roundtable series assesses the use of antibody-drug conjugates plus chemoimmunotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

This roundtable series explores tyrosine kinase inhibitor use and other treatments for patients with renal cell carcinoma, as discussed by participants at virtual live events.

This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.

This roundtable series gauges the use of combination CD19 inhibition and chemotherapy in the previously treated diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

This roundtable series considers the use of immunotherapy-based combinations as treatment for non–small cell lung cancer, regardless of the patient’s PD-L1 expression, as discussed by participants at virtual live events.

This roundtable series evaluates the use of therapies such as monoclonal antibodies in advanced non–small cell lung cancer with high PD-L1 expression, as discussed by participants at virtual live events.